Voyager Therapeutics (NASDAQ:VYGR) received a $35.00 price target from Canaccord Genuity in a research note issued on Wednesday. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity’s price target indicates a potential upside of 51.12% from the company’s previous close.
Several other equities analysts have also issued reports on VYGR. Wedbush restated an “outperform” rating and set a $26.00 price target (up from $22.00) on shares of Voyager Therapeutics in a research note on Monday, November 20th. Piper Jaffray Companies restated an “overweight” rating and set a $28.00 price target on shares of Voyager Therapeutics in a research note on Tuesday, November 28th. BTIG Research started coverage on Voyager Therapeutics in a research note on Tuesday, December 19th. They set a “buy” rating and a $32.00 price target on the stock. BidaskClub upgraded Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, January 5th. Finally, Zacks Investment Research upgraded Voyager Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, January 6th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $30.10.
Shares of Voyager Therapeutics (NASDAQ:VYGR) traded down $1.10 on Wednesday, reaching $23.16. The company had a trading volume of 698,561 shares, compared to its average volume of 434,949. Voyager Therapeutics has a 1 year low of $8.10 and a 1 year high of $31.91. The company has a market capitalization of $763.59, a price-to-earnings ratio of -8.15 and a beta of 2.37.
Several hedge funds have recently added to or reduced their stakes in VYGR. Teachers Advisors LLC grew its stake in shares of Voyager Therapeutics by 24.7% in the 2nd quarter. Teachers Advisors LLC now owns 25,685 shares of the company’s stock valued at $230,000 after purchasing an additional 5,081 shares during the period. TIAA CREF Investment Management LLC boosted its holdings in shares of Voyager Therapeutics by 11.8% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 37,295 shares of the company’s stock worth $334,000 after acquiring an additional 3,939 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of Voyager Therapeutics by 26.8% in the 2nd quarter. Northern Trust Corp now owns 133,571 shares of the company’s stock worth $1,197,000 after acquiring an additional 28,222 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Voyager Therapeutics by 3.2% in the 2nd quarter. Vanguard Group Inc. now owns 430,765 shares of the company’s stock worth $3,860,000 after acquiring an additional 13,194 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Voyager Therapeutics by 232.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 98,128 shares of the company’s stock worth $879,000 after acquiring an additional 68,574 shares in the last quarter. Institutional investors own 80.03% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Canaccord Genuity Analysts Give Voyager Therapeutics (VYGR) a $35.00 Price Target” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2018/03/14/canaccord-genuity-analysts-give-voyager-therapeutics-vygr-a-35-00-price-target.html.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.